WEE1 and neoplasm: An initial phase II clinical trial evaluating the anti-tumor effects of a WEE1 inhibitor in recurrent serous endometrial carcinoma found that recurrence-free survival at 6 months achieved 47.1%, suggesting the potential therapeutic promise of WEE1 inhibitors in endometrial cancer20.